Get started
Author

Melody Becnel

Observed names: M. Becnel, M.R. Becnel, Melody R Becnel, Melody R. Becnel, Melody Renee Becnel
ORCID: 0000-0001-6295-5433
Observed ORCID: 0000-0001-6295-5433
OpenAlex ID: A5001970750
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma
2019 · Roberto Carmagnani Pestana, Melody Becnel, et al. · Oral Oncology · 61
Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease
2023 · Minghao Dang, Guangchun Han, et al. · Cancer Cell · 54
PDF
Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
2019 · Melody R. Becnel, Loretta J. Nastoupil, et al. · British Journal of Haematology · 52
PDF
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
2018 · Brian T. Hill, Loretta Nastoupil, et al. · British Journal of Haematology · 51
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
2021 · Raphael E. Steiner, Jose Banchs, et al. · Haematologica · 50
PDF
A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
2020 · Swami P. Iyer, Jie Xu, et al. · Blood · 26
Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
2020 · Melody R Becnel, Sandra B. Horowitz, et al. · Blood · 25
Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation
2017 · Melody Becnel, Christopher R. Flowers, et al. · Annals of Lymphoma · 23
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
2020 · Melody R. Becnel, Hans C. Lee · Therapeutic Advances in Hematology · 22
Follicular Lymphoma: Past, Present, and Future
2018 · Melody R. Becnel, Loretta J. Nastoupil · Current Treatment Options in Oncology · 16
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
2025 · Satabdi Saha, Lubna Rehman, et al. · Blood Advances · 15
PDF
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
2024 · Oren Pasvolsky, Curtis Marcoux, et al. · Blood Cancer Journal · 11
PDF
Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma.
2022 · Melody Becnel, Christopher J. Ferreri, et al. · Journal of Clinical Oncology · 10
Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival
2018 · Allison M. Winter, Loretta J. Nastoupil, et al. · Blood · 10
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis
2022 · B.R. Shank, B. Primeaux, et al. · Clinical Lymphoma Myeloma & Leukemia · 7
PDF
Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study
2025 · Tali Shafat, Daniel De-la-Rosa-Martinez, et al. · Open Forum Infectious Diseases · 6
ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).
2023 · Elisabet Esteve Manasanch, Neha Korde, et al. · Journal of Clinical Oncology · 6
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience
2022 · Meera Mohan, Melody Renee Becnel, et al. · American Journal of Hematology · 6
PDF
Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens
2018 · Melody R. Becnel, M Laura Rubin, et al. · Blood · 6
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy
2024 · Gohar S. Manzar, Stephanie O. Dudzinski, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
Disease Characteristics of Multiple Myeloma Involving BRAF Mutations
2021 · Shehab Fareed Mohamed, Maliha Khan, et al. · Blood · 5
Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
2022 · Owhofasa O. Agbedia, Rishab Prakash, et al. · Blood · 4
Current and future status of stem cell expansion
2018 · Melody Becnel, Elizabeth J. Shpall · Current Opinion in Hematology · 4
Use of Intrathecal Chemotherapy for Corticosteroid-Refractory Icans in B-Cell Lymphoma Patients Treated with CART
2024 · Paolo Strati, Sandra Horowitz, et al. · Transplantation and Cellular Therapy · 3
SARS-CoV-2 in multiple myeloma: initial observation and management
2020 · Elisabet E. Manasanch, Victor Mulanovich, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
Works count: 90
Citation count: 506
H-index: 11
I10-index: 14
Year
Topic
Type